 |
|
The Neurological Masquerade of Intravascular Lymphomatosis
Xabier Beristain, MD;
Biagio Azzarelli, MD
Arch Neurol. 2002;59:439-443.
ABSTRACT
| |
Background Intravascular lymphomatosis (IVL) is an uncommon systemic disease characterized
by occlusion of small vessels by malignant lymphomatous cells. Central nervous
system involvement usually presents as subacute encephalopathy, dementia,
seizures, or multifocal cerebrovascular events.
Objective To increase awareness about IVL, an uncommon cause of neurological disease.
Design This is a retrospective case series of 8 pathologically proved cases
of IVL with neurological disease. Patients were part of a pathological series
collected between April 1962 and October 1998 at Indiana University School
of Medicine and the Armed Forces Institute of Pathology, Washington, DC.
Setting Neurological and neuropathological examinations were performed at tertiary
referral hospitals.
Patients Eleven patients were diagnosed pathologically as having IVL, but 3 were
not included in this evaluation because of a lack of appropriate clinical
information. Of the final sample (n = 8), there were 4 men and 4 women (mean
± SD age, 62.9 ± 9.9 years).
Results All 8 patients had focal neurological deficits, 7 had encephalopathy
or dementia, 5 had epileptic seizures, and 2 had myelopathy. Death occurred
at a mean of 7.7 months (range, 1-24 months) after the onset of symptoms.
All patients had elevated cerebrospinal fluid protein levels, 4 had pleocytosis,
and 2 had an elevated IgG level in their cerebrospinal fluid. Of the 4 patients
who underwent a brain biopsy, 1 was diagnosed as having IVL before death.
Conclusions Intravascular lymphomatosis is an uncommon disease with a myriad of
potential neurological manifestations. Diagnosis requires a high index of
suspicion and a pathological examination. If diagnosed early, aggressive chemotherapy
is potentially curative, although the overall prognosis remains dismal.
INTRODUCTION
INTRAVASCULAR lymphomatosis (IVL), also known as angiotropic large-cell
lymphoma or malignant angioendotheliomatosis, is an uncommon systemic disease
characterized by the occlusion of arterioles, capillaries, and venules throughout
the body by malignant lymphomatous cells. The signs and symptoms of the disorder
are attributed to vascular occlusion.1-2
Of the patients with IVL, 75% to 85% have central nervous system (CNS) involvement
and more than 90% may develop multifocal cerebrovascular events, dementia,
subacute encephalopathy, seizures, and myelopathy. Neuropathies, radiculopathies,
and myopathies are also possible.3-5
Other organs may be involved, including the kidneys, the liver, the lungs,
the prostate, skin, and the thyroid gland. However, hematopoietic organs are
usually spared.4-5 Because of
the lack of involvement of the reticuloendothelial system, peripheral blood,
or bone marrow by the lymphomatous process, diagnosis is often delayed or
determined at autopsy.6-13
Spontaneous remission in untreated patients is possible,14
but the clinical course is usually fatal in a few weeks to several months.10, 15-16 However, aggressive
chemotherapy early in the disease process increases survival and is potentially
curative.17
PATIENTS AND METHODS
This is a retrospective case series evaluation of 8 patients from a
sample of 11 persons with pathologically proved IVL who were examined at Indiana
University School of Medicine and the Armed Forces Institute of Pathology
between April 1962 and October 1998.18 The
3 patients eliminated from this description did not have adequate clinical
information available for review. They were men, aged 32, 47, and 76 years.
The 32-year-old patient had a myelopathy and a brain lesion that, after biopsy,
confirmed the diagnosis of IVL. Of the remaining 8 patients with IVL described
in this series, 1 had a Mycobacterium marinum infection,
and we described him previously.19 Of the 8
patients, 4 were men and 4 were women (mean ± SD age, 62.9 ±
9.9 years; range, 42-74 years). All of them were white. Details regarding
demographic characteristics and clinical findings are shown in Table 1.
|
|
|
|
Table 1. Demographic Characteristics, Neurological Symptoms, and Complementary
Data in Patients With IVL*
|
|
|
RESULTS
Intravascular lymphomatosis was fatal within a mean ± SD of 7.7
± 7.6 months (range, 1-24 months) of the onset of symptoms. All patients
developed focal neurological deficits, and multiple brain regions were affected.
The most common focal deficits were motor and sensory deficits (n = 6) and
aphasia (n = 5). Less frequently, dysarthria, apraxia, incoordination, cogwheel
rigidity, and akinetic mutism were found. Four patients initially presented
with mental status changes, and 3 developed them during the later stage of
the disease. Mental status changes included confusional states with a fluctuating
level of alertness and a decline in cognitive status with rapidly progressive
dementia. Two patients had myelopathy with paraparesis and urinary incontinence.
Of these 2 patients, 1 (patient 5) initially had an undifferentiated malignant
lymphoma and underwent pelvic and lumbar spine radiation therapy plus cyclophosphamide
administration, with improvement of symptoms for 8 months, when she developed
sudden global aphasia, right hemiparesis, and generalized seizures. This patient
died 1 year after the beginning of symptoms. Five patients had epileptic seizures.
In 4 of them, the seizures were focal and tended to occur with more advanced
disease. One patient with rapidly progressive dementia (patient 4) developed
multifocal startle myoclonus and was thought to have Creutzfeldt-Jakob disease
until a postmortem brain biopsy specimen demonstrated IVL. Another patient
with focal neurological findings and progressive dementia (patient 6) was
thought to have Creutzfeldt-Jakob disease when the brain biopsy specimen showed
evidence of neuronal lipid degeneration and astrocytic gliosis. Weight loss,
fever, and malaise were present in 5 patients. Two patients had skin manifestations:
one had a maculopapular rash on the left hand, and the other presented with
generalized eczema. The latter patient underwent a skin biopsy, and the biopsy
specimen showed perivascular infiltration suggestive of a chronic inflammatory
process.
All the patients had elevated protein levels in their cerebrospinal
fluid (CSF). Four patients had mild pleocytosis, and only 1 had atypical cells.
Two patients had high levels of lactate dehydrogenase, and 3 had anemia. One
patient (patient 8) had elevated levels of antinuclear antibodies (1:5120)
and phosphatidylethanolamine (IgM 8 multiples of the mean [normal values  4
multiples of the mean]). This patient responded transiently to corticosteroids
and was thought to have primary CNS angiitis until autopsy, when the diagnosis
of IVL was confirmed. One patient had a history of Waldenström macroglobulinemia.
This patient developed focal and diffuse neurological deficits, with no laboratory
evidence of hyperviscosity syndrome.
Only 1 of 3 brain biopsy specimens obtained during life was diagnostic
for IVL (in patient 3). Patient 3, at diagnosis, had a terminal prognosis
and no chemotherapy was recommended; this patient died 2 months after the
beginning of symptoms. The nondiagnostic biopsy specimens were not reevaluated,
and both included samples of the leptomeninges. All the patients underwent
an autopsy, except for a patient (patient 4) who underwent a postmortem brain
needle biopsy for suspected Creutzfeldt-Jakob disease. Two patients had an
autopsy that was limited to a brain evaluation. All patients had intraluminal
lymphoma cell accumulation. Capillaries and veins were the vessels more commonly
involved. Two patients had an extravascular extension of lymphoma cells, and
one of them had a neoplastic perivascular infiltrate. Details regarding the
pathological findings are shown in Table
2.
|
|
|
|
Table 2. Pathological Findings*
|
|
|
COMMENT
Most publications on IVL are either single case reports or short series.
To our knowledge, this is the largest series of patients with neurological
manifestations of IVL. According to the literature, the age of onset is in
the sixth decade of life, with a male-female ratio between 1:1 and 2:1. Encephalopathy
or cognitive decline is present in 85% of the patients, and focal symptoms
are present in 67% to 82% of the patients.1-2,4, 6-13,15, 20-21
Seizures affect one fourth of the patients.10, 12
Most frequently, seizures are generalized and occur late in the course of
the disease.10 Myoclonus may affect patients
with IVL, occasionally leading to the erroneous diagnosis of Creutzfeldt-Jakob
disease.8 The clinical findings and demographic
data in our patients are consistent with previous reports.1-5,9-10,21
Intravascular lymphomatosis may occur in patients with a history of follicular
small cleaved cell lymphoma20 and in patients
with Waldenström macroglobulinemia,21
as was the case in 2 of our patients.
Dermatological manifestations are present in up to one third of the
patients with IVL. These include nodules, indurated plaques, and telangiectasis.12, 22-23 Constitutional symptoms,
such as fever, weight loss, malaise, or asthenia, affect 25% to 50% of these
patients.10, 12 Death typically
ensues between 5 and 11.4 months after disease onset, but may occur within
a few days or as late as 33 months.2, 5-6,10
Intravascular lymphomatosis is a known mimicker of primary angiitis of the
CNS7, 13-14; this
was the diagnosis of one of our patients until an autopsy was performed. This
patient had elevated titers of antinuclear antibodies and antiphospholipid
antibodies, conditions seen in patients with IVL and non-Hodgkin lymphoma.7, 24
There are 4 frequent laboratory abnormalities in patients with IVL:
anemia, an elevated erythrocyte sedimentation rate, an elevated lactate dehydrogenase
level, and an elevated CSF protein concentration. According to the literature,1-3,5-13,15
45% of patients develop anemia, 75% have an elevated erythrocyte sedimentation
rate, 85% have a lactate dehydrogenase level above 250 U/L, and 90% have an
elevated CSF protein concentration. More than half of the patients have pleocytosis,
and 3% have atypical cells in the CSF. IgG elevation in the CSF is also possible.1-3,5-13,15
These findings were present in our patients.
A common observation is the occasionally dramatic but transient response
to corticosteroid treatment.9-10,12, 15
Different chemotherapeutic regimens have been attempted in patients with IVL,15 including M-BACOD (methotrexate, bleomycin sulfate,
doxorubicin hydrochloride [Adriamycin], cyclophosphamide, vincristine sulfate,
and dexamethasone), CHOP (cyclophosphamide, doxorubicin (Adriamycin), vincristine,
and prednisone), COPP (cyclophosphamide, vincristine, procarbazine hydrochloride,
and prednisone), and BACOP (bleomycin, doxorubicin [Adriamycin], cyclophosphamide,
vincristine, and prednisone). There is evidence17
that aggressive chemotherapy after early diagnosis may induce remission and
is potentially curative. However, the overall prognosis of patients with IVL
remains dismal.
Most of the cases reported in the literature1-2,10-11,13, 25
are postmortem evaluations or are diagnosed after a biopsy. Malignant lymphocytes
usually show B-cell lineage,12 and T-lymphocyte
IVL is rare.25 The characteristic microscopic
findings are distention and occlusion of small cerebral and meningeal blood
vessels by neoplastic mononuclear cells. Usually these cells are noncohesive
and free in the lumina. Blood vessels may also show parietal infiltration
by malignant cells, especially in subendothelial areas. However, most of the
time this infiltration is caused by mature T lymphocytes.1-2,11-12
Only in rare instances do malignant cells extend beyond the vessel walls into
the adjacent parenchyma.12, 26
The neoplastic cells within the vascular lumina are frequently associated
with thrombosis, resulting in ischemic infarcts of neural tissue.10 Vessel involvement is best seen adjacent to areas
of infarction and necrosis.4 Brain infarcts
or hemorrhages are common in patients with IVL. On the other hand, hematopoietic
organ involvement is an uncommon feature, and only one of our patients had
involvement of the spleen. Other organs that may be affected by IVL are the
lungs, the kidneys, the prostate, the liver, the gastrointestinal tract, the
thyroid gland, the heart, the adrenal glands, skin, muscle, and the peripheral
nerves.1-2,4-13,15, 20, 25
A condition that mimics IVL is lymphomatoid granulomatosis. This is
a perivascular infiltrative lymphoma that, unlike IVL, is of T-lymphocyte
lineage. Both conditions may involve the CNS and produce symptoms of dementia,
multifocal infarcts, and seizures. Unlike the periventricular and white matter
lesions seen in patients with IVL, lymphomatoid granulomatosis tends to involve
the small vessels of the leptomeninges and the cortical blood vessels, causing
diffuse cerebral atrophy without white matter changes on a magnetic resonance
imaging scan.27
The reasons for the intravascular localization of the neoplastic cells
and their predilection to involve the CNS are not completely understood. It
is known that endothelial cells can express surface receptors that facilitate
lymphocyte attachment. Lymphocytes also have surface receptors for endothelial
cells. An alteration in the normal interaction of endothelial cells and lymphocyte
homing surface receptors on the neoplastic cells may be responsible for the
intravascular location of the tumor. In addition, vessels of different organs
might have organ-specific receptors.1, 3, 28
The reason for the vascular occlusion in patients with IVL remains unclear.
Most reports comment on the accumulation of atypical cells as the cause of
the vascular occlusion. The origin of this intravascular accumulation is probably
multifactorial. For instance, patients with IVL may present with hemolytic
anemia, thrombotic microangiopathy, and disseminated intravascular coagulation.
Thrombotic microangiopathy could have started after endothelial damage, leading
to platelet activation, thrombocytopenia, red cell fragmentation, and microthrombi
formation.6 Although this could be a reasonable
explanation, none of our patients had clear evidence of disseminated intravascular
coagulation, and we have not found any evidence supporting an important role
for disseminated intravascular coagulation as a cause of vascular occlusion
in patients with IVL. In the case of thrombotic microangiopathy, endothelial
injury might be caused either by tumor-derived factors or by direct interaction
of tumor cells with endothelial cells.6
Elevated antiphospholipid antibodies, including anticardiolipin antibodies
and the lupuslike anticoagulant, may be seen in two thirds of patients with
acute myelogenous leukemia and in almost half of patients with non-Hodgkin
lymphoma, respectively.24 This was the case
in one of our patients who had an elevation of the phosphatidylethanolamine
level. This could explain the tendency toward a prothrombotic state and partially
account for the vascular occlusion in these patients.
In summary, IVL is a rare systemic disease that causes a myriad of neurological
symptoms, including focal neurological deficits, cognitive decline, and seizures.
Diagnosing IVL is challenging because the signs and symptoms are nonspecific
and there is no diagnostic test other than a pathological examination. This
lack of reliable ancillary tests delays the diagnosis and limits the efficacy
of potentially curative chemotherapy. For this reason, the examination of
these patients requires a high index of suspicion and an aggressive workup.
This should include computed tomography or magnetic resonance imaging of the
thorax, abdomen, and pelvis to examine organs usually involved in persons
with IVL; a biopsy of the affected skin or viscera, and recommend brain with
meningeal biopsy for those cases in which there is no other more accessible
source of affected tissue. In cases in which a brain biopsy is to be performed,
it is of utmost importance to include leptomeninges in the biopsy material
(ideally, a cubic centimeter of cerebral cortex, subcortical white matter,
and leptomeninges). In patients with IVL, the tissue fixed with formaldehyde
solution is the most informative, because it is used for phenotyping of the
malignant cells by immunohistochemistry.
The physiopathological features of this disorder are thought to be related
to vascular occlusion, although the precise mechanisms of vascular-cellular
interaction leading to vascular occlusion and thrombotic events are not clear.
Further research to elucidate the mechanisms of vascular occlusion and identification
of the factors that predispose to CNS involvement will be required to help
develop more effective treatments for IVL.
AUTHOR INFORMATION
Accepted for publication August 30, 2001.
Author contributions: Study
concept and design (Drs Beristain and Azzarelli); acquisition of data (Dr Azzarelli); analysis and
interpretation of data (Drs Beristain and Azzarelli); drafting of the manuscript (Dr Beristain); critical
revision of the manuscript for important intellectual content (Drs
Beristain and Azzarelli); administrative, technical, or
material support (Drs Beristain and Azzarelli); and supervision (Dr Azzarelli).
Corresponding author and reprints: Xabier Beristain, MD, Department
of Neurology, Indiana University School of Medicine, 545 Barnhill Dr, Emerson
Hall, Suite 125, Indianapolis, IN 46202 (e-mail: xberista{at}iupui.edu).
From the Departments of Neurology (Dr Beristain) and Neuropathology
(Dr Azzarelli), Indiana University School of Medicine, Indianapolis.
REFERENCES
| |
1. Daniel SE, Rudge P, Scaravilli F. Malignant angioendotheliosis involving the nervous system: support
for a lymphoid origin of the neoplastic cells. J Neurol Neurosurg Psychiatry. 1987;50:1173-1177.
ABSTRACT
2. Petito CK, Gottlieb GJ, Dougherty JH, Petito FA. Neoplastic angioendotheliosis: ultrastructural study and review of
the literature. Ann Neurol. 1978;3:393-399.
FULL TEXT
|
ISI
| PUBMED
3. Prayson RA. Angiotropic large cell lymphoma: simultaneous peripheral nerve and
skeletal muscle involvement. Pathology. 1996;28:25-27.
FULL TEXT
|
ISI
| PUBMED
4. Collins KA, Davis GJ. Angiotropic large cell lymphoma. South Med J. 1995;88:235-238.
ISI
| PUBMED
5. Roux S, Grossin M, De Bandt M, Palazzo E, Vachon F, Kahn MF. Angiotropic large cell lymphoma with mononeuritis multiplex mimicking
systemic vasculitis. J Neurol Neurosurg Psychiatry. 1995;58:363-366.
ABSTRACT
6. Sill H, Höfler G, Kaufmann P, et al. Angiotropic large cell lymphoma presenting as thrombotic microangiopathy
(thrombotic thrombocytopenic purpura). Cancer. 1995;75:1167-1173.
FULL TEXT
|
ISI
| PUBMED
7. Sienknecht CW, Whetsell WO, Pollock P. Intravascular malignant lymphoma ("malignant angioendotheliomatosis")
mimicking primary angiitis of the central nervous system. J Rheumatol. 1995;22:1769-1770.
ISI
| PUBMED
8. Drlicek M, Grisold W, Liszka U, Hitzenberger P, Machacek E. Angiotropic lymphoma (malignant angioendotheliomatosis) presenting
with rapidly progressive dementia. Acta Neuropathol (Berl). 1991;82:533-535.
FULL TEXT
| PUBMED
9. Sunohara N, Mukoyama M, Satoyoshi E. Neoplastic angioendotheliosis of the central nervous system. J Neurol. 1984;231:14-19.
FULL TEXT
|
ISI
| PUBMED
10. Smadja D, Mas JL, Fallet-Bianco C, et al. Intravascular lymphomatosis (neoplastic angioendotheliosis) of the
central nervous system: case report and literature review. J Neurooncol. 1991;11:171-180.
FULL TEXT
| PUBMED
11. Bots GT. Angioendotheliomatosis of the central nervous system. Acta Neuropathol (Berl). 1974;28:75-78.
FULL TEXT
| PUBMED
12. Davis JE, Davis LE, Kornfeld M, Mandler RN. Neurologic manifestations of intravascular lymphomatosis. Acta Neurol Scand. 1995;91:494-499.
ISI
| PUBMED
13. Lie JT. Malignant angioendotheliomatosis (intravascular lymphomatosis) clinically
simulating primary angiitis of the central nervous system. Arthritis Rheum. 1992;35:831-834.
ISI
| PUBMED
14. LeWitt PA, Forno LS, Brant-Zawadski M. Neoplastic angioendotheliosis: a case with spontaneous regression and
radiographic appearance of cerebral arteritis. Neurology. 1983;33:39-44.
FREE FULL TEXT
15. Williams DB, Lyons MK, Yanagihara T, Colgan J, Banko PM. Cerebral angiotropic large cell lymphoma (neoplastic angioendotheliosis):
therapeutic considerations. J Neurol Sci. 1991;103:16-21.
FULL TEXT
|
ISI
| PUBMED
16. Ko YH, Han JH, Go JH, et al. Intravascular lymphomatosis: a clinicopathological study of two cases
presenting as an interstitial lung disease. Histopathology. 1997;31:555-562.
FULL TEXT
|
ISI
| PUBMED
17. Baumann TP, Hurwitz N, Karamitopolou-Diamantis E, Probst A, Herrmann R, Steck AJ. Diagnosis and treatment of intravascular lymphomatosis. Arch Neurol. 2000;57:374-377.
FREE FULL TEXT
18. Beristain X, Azzarelli B. The neurological masquerade of intravascular lymphomatosis [abstract]. Neurology. 2000;54(suppl 3):159A.
19. Sokol DK, Azzarelli B, Smith RR, et al. Primary intravascular lymphomatosis associated with Mycobacterium marinum. J Neuroimaging. 1998;8:47-49.
FULL TEXT
| PUBMED
20. Carter DK, Batts KP, de Groen PC, Kurtin PJ. Angiotropic large cell lymphoma (intravascular lymphomatosis) occurring
after follicular small cleaved cell lymphoma. Mayo Clin Proc. 1996;71:869-873.
ISI
| PUBMED
21. Glass J, Hochberg FH, Miller DC. Intravascular lymphomatosis: a systemic disease with neurologic manifestations. Cancer. 1993;71:3156-3164.
FULL TEXT
|
ISI
| PUBMED
22. Wilson BB. Indurated telangiectatic plaques: malignant angioendotheliomatosis
(MAE). Arch Dermatol. 1992;128:255-258.
23. Requena L, Saguenza OP. Cutaneous vascular proliferations, part III: malignant neoplasms, other
cutaneous neoplasms with significant vascular component, and disorders erroneously
considered as vascular neoplasms. J Am Acad Dermatol. 1998;38:143-175.
FULL TEXT
|
ISI
| PUBMED
24. Sciarra A, Stasi R, Stipa E, et al. Anticorpi anti-fosfolipidi: prevalenza, significato clinico e correlazione
con i livelli di citochine nella leucemia mieloide acuta e nel linfoma non-Hodgkin. Recenti Prog Med. 1995;86:57-62.
PUBMED
25. Au WY, Shek WH, Nicholls J, Tse KM, Todd D, Kwong YL. T-cell intravascular lymphomatosis (angiotropic large cell lymphoma):
association with Epstein-Barr viral infection. Histopathology. 1997;31:563-567.
FULL TEXT
|
ISI
| PUBMED
26. Azzarelli B, Roessmann U. Pathogenesis of central nervous system infiltration in acute leukemia. Arch Pathol Lab Med. 1977;101:203-205.
ISI
| PUBMED
27. Kleinschmidt-DeMasters MD, Filley CM, Bitter MA. Central nervous system angiocentric, angiodestructive T-cell lymphoma
(lymphomatoid granulomatosis). Surg Neurol. 1992;37:130-137.
FULL TEXT
|
ISI
| PUBMED
28. Azzarelli B, Easterling K, Norton JA. Leukemic cell–endothelial cell interactions in leukemic cell
dissemination. Lab Invest. 1989;60:45-64.
ISI
| PUBMED
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(3):492-494.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Myelopathy but normal MRI: where next?
Wong et al.
PN 2008;8:90-102.
ABSTRACT
| FULL TEXT
Intravascular Large B-Cell Lymphoma Presenting as Cerebellar and Cerebral Infarction
Holmoy et al.
Arch Neurol 2007;64:754-755.
FULL TEXT
Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment
Singh et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:342-349.
ABSTRACT
| FULL TEXT
Clinical problem-solving. Heading down the wrong path.
Detsky et al.
NEJM 2006;355:67-74.
FULL TEXT
Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor
Kawahara et al.
Neurology 2004;63:1731-1733.
ABSTRACT
| FULL TEXT
A Case of Intravascular Lymphoma with Increased Regional Cerebral Blood Flow in I-123 IMP Single-Photon Emission CT
Miyazaki et al.
Am. J. Neuroradiol. 2004;25:565-570.
ABSTRACT
| FULL TEXT
|
